BioInvent International AB
BIOI-B.STNext catalyst
BI-1910
Solid Tumors
Get an email about BIOI-B.ST's next catalysts
Track BioInvent International AB (BIOI-B.ST) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
Plus 1 more upcoming event in our data (Phase 2 readout).See the timeline
2 upcoming, 0 past
BI-1910 Phase 2 Est. Readout
Primary completion for BI-1910 trial (NCT06205706) in Solid Tumors
SourceBI-1206 Phase 2 Est. Readout
Estimated primary completion for Acalabrutinib trial (NCT03571568) in Indolent B-Cell Non-Hodgkin Lymphoma. Topline data typically follows completion by weeks to months.
SourceMarket Overview
Stock performance and key metrics
pembrolizumab (KEYTRUDA®)
Melanoma Metastatic
BI-1808
Advanced Malignancies
BI-1910
Solid Tumors
BI1206
Solid Tumor, Adult
BI-1206
Indolent B-Cell Non-Hodgkin Lymphoma
TB-402
Total Knee Replacement Surgery
MLDL1278A
Atherosclerosis
Rivaroxaban
Prophylaxis of Venous Thromboembolic Events
BI-1206 single agent dose escalation phase
B-cell Lymphoma
Ipilimumab (YervoyTM,/solution)
Melanoma Metastatic
Combination of BI-1206 with rituximab expansion phase
B-cell Lymphoma
statin, stable dose
Atherosclerosis
Combination of BI-1206 with rituximab escalation phase
B-cell Lymphoma
BI-1607
Melanoma Metastatic
BI-1206 single agent expansion phase
B-cell Lymphoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
pembrolizumab (KEYTRUDA®) | Phase 2 | Melanoma Metastatic | - | - |
BI-1808 | Phase 2 | Advanced Malignancies | - | - |
BI-1910 | Phase 2 | Solid Tumors | - | - |
BI1206 | Phase 2 | Solid Tumor, Adult | - | - |
BI-1206 | Phase 2 | Indolent B-Cell Non-Hodgkin Lymphoma | - | - |
TB-402 | Phase 2 | Total Knee Replacement Surgery | - | - |
MLDL1278A | Phase 2 | Atherosclerosis | - | - |
Rivaroxaban | Phase 2 | Prophylaxis of Venous Thromboembolic Events | - | - |
BI-1206 single agent dose escalation phase | Phase 2 | B-cell Lymphoma | - | - |
Ipilimumab (YervoyTM,/solution) | Phase 2 | Melanoma Metastatic | - | - |
Combination of BI-1206 with rituximab expansion phase | Phase 2 | B-cell Lymphoma | - | - |
statin, stable dose | Phase 2 | Atherosclerosis | - | - |
Combination of BI-1206 with rituximab escalation phase | Phase 2 | B-cell Lymphoma | - | - |
BI-1607 | Phase 2 | Melanoma Metastatic | - | - |
BI-1206 single agent expansion phase | Phase 2 | B-cell Lymphoma | - | - |
Frequently asked questions
What is in BioInvent International AB's drug pipeline?→
CatalystAlert tracks 15 drug candidates in BioInvent International AB's (BIOI-B.ST) pipeline across Phase 2. Its lead program is BI-1206 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is BioInvent International AB's next FDA catalyst?→
BioInvent International AB's (BIOI-B.ST) next tracked catalyst is a Phase 2 readout expected Q3 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track BIOI-B.ST biotech catalysts?→
Add BIOI-B.ST to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow BioInvent International AB's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.
